NASDAQ:MBIO Mustang Bio Q1 2026 Earnings Results & Report $0.40 -0.02 (-4.05%) As of 10/9/2026 04:00 PM Eastern Mustang Bio beat analyst earnings expectations in its Q1 2026 results, released May 5, 2026. The company reported EPS of -$0.14 versus the -$140.00 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 5, 2026TimeAfter Market ClosesConference Call7:00 AM ET Mustang Bio EPS ResultsActual EPS-$0.14Consensus EPS -$140.00Beat/MissBeat by +$139.86One Year Ago EPSN/AEPS Beat Rate3 of last 4 quartersMustang Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsMustang Bio's Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Mustang Bio Q1 2026 Earnings FAQ Did Mustang Bio beat earnings estimates for Q1 2026? Mustang Bio (NASDAQ:MBIO) reported earnings of -$0.14 per share for Q1 2026, beating the consensus estimate of -$140.00. The report was announced on Tuesday, May 5, 2026. When is Mustang Bio's next earnings date? Mustang Bio's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Mustang Bio on the company's earnings history page. Mustang Bio Earnings HeadlinesMindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection KiosksJune 9, 2026 | globenewswire.comMindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment SolutionMay 14, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.May 12, 2026 | globenewswire.comMindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication DetectionMay 12, 2026 | globenewswire.comMustang Bio Inc.July 25, 2025 | barrons.comSee More Mustang Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mustang Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mustang Bio and other key companies, straight to your email. Email Address About Mustang BioMustang Bio (NASDAQ:MBIO) is a clinical-stage biotechnology company focused on developing cell and gene therapies for cancer and other serious diseases. The company has historically operated as a subsidiary of Fortress Biotech and has concentrated on engineered T-cell therapies designed to recognize and attack specific tumor targets. Its development programs have included MB-106, an investigational CD20-targeted CAR T-cell therapy for certain B-cell malignancies, and MB-101, an investigational CAR T-cell therapy targeting IL13Rα2 for glioblastoma and other central nervous system tumors. Mustang Bio has also pursued related next-generation and combination approaches intended to improve the persistence, safety, or effectiveness of these therapies. Mustang Bio’s programs have primarily been developed through research and clinical collaborations in the United States, including relationships with academic and medical institutions. The company’s therapies remain investigational and have not been established as approved commercial products. Mustang Bio was founded in 2015 and has historically been led by executives with experience in biotechnology, oncology, and cell therapy development.View Mustang Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
